Evidence map›Paper›PMID 36105983›Full record

ArticleRSC advances2022

New dimeric chromanone derivatives from the mutant strains of

Guowei Gu, Tao Zhang, Jianyuan Zhao, Wuli Zhao, Yan Tang, Lu Wang, Shan Cen, Liyan Yu, Dewu Zhang

Abstract read
In one paragraph

Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guowei GuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.
Tao ZhangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.
Jianyuan ZhaoInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.
Wuli ZhaoInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.
Yan TangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.
Lu WangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.
Shan CenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.
Liyan YuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.
Dewu ZhangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 P. R. China yly@cpcc.ac.cn zhangdewuever@163.com.ORCID https://orcid.org/0000-0001-6289-0617

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three new chromanone dimer derivatives, paecilins F-H (1-3) and ten known compounds (4-13), were obtained from the mutant strains of

Identifiers

PMID36105983
PMCPMC9364356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.